These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

706 related items for PubMed ID: 22450212

  • 1. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Agarwal S, Hachamovitch R, Menon V.
    Arch Intern Med; 2012 Apr 23; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
    [Abstract] [Full Text] [Related]

  • 2. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov 23; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.
    Adv Ther; 2012 Jun 23; 29(6):491-507. PubMed ID: 22684583
    [Abstract] [Full Text] [Related]

  • 4. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.
    Am J Geriatr Pharmacother; 2009 Jun 23; 7(3):159-66. PubMed ID: 19616184
    [Abstract] [Full Text] [Related]

  • 5. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 6. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.
    Clin Ther; 2013 Jul 24; 35(7):967-984.e2. PubMed ID: 23870607
    [Abstract] [Full Text] [Related]

  • 7. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB, ARISTOTLE Investigators.
    J Am Coll Cardiol; 2013 Jul 24; 63(1):52-61. PubMed ID: 24055845
    [Abstract] [Full Text] [Related]

  • 8. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW.
    Hosp Pract (1995); 2011 Oct 24; 39(4):7-16. PubMed ID: 22056819
    [Abstract] [Full Text] [Related]

  • 9. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C, Singh BN.
    Minerva Cardioangiol; 2004 Apr 24; 52(2):125-39. PubMed ID: 15194994
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):472-9. PubMed ID: 22740012
    [Abstract] [Full Text] [Related]

  • 11. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
    Connolly SJ.
    Am Heart J; 2003 Mar 01; 145(3):418-23. PubMed ID: 12660663
    [Abstract] [Full Text] [Related]

  • 12. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006 Mar 01; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 13. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H, Selçuk MT, Maden O.
    Anadolu Kardiyol Derg; 2007 Mar 01; 7(1):54-8. PubMed ID: 17347079
    [Abstract] [Full Text] [Related]

  • 14. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
    Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES, Kim SK, Choi DH, Kim YH, Pak HN.
    J Cardiovasc Electrophysiol; 2010 May 01; 21(5):501-7. PubMed ID: 20021521
    [Abstract] [Full Text] [Related]

  • 15. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY, Frison L, Halperin JL, Lane DA.
    J Am Coll Cardiol; 2011 Jan 11; 57(2):173-80. PubMed ID: 21111555
    [Abstract] [Full Text] [Related]

  • 16. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M, AFFIRM Investigators.
    Am Heart J; 2005 Apr 11; 149(4):650-6. PubMed ID: 15990748
    [Abstract] [Full Text] [Related]

  • 17. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM, ROCKET AF Steering Committee and Investigators.
    Circulation; 2013 Jan 15; 127(2):224-32. PubMed ID: 23212720
    [Abstract] [Full Text] [Related]

  • 18. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW, SPORTIF Investigators.
    Am J Manag Care; 2004 Dec 15; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW.
    Am J Cardiol; 2012 Apr 01; 109(7):1020-5. PubMed ID: 22221944
    [Abstract] [Full Text] [Related]

  • 20. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S, Bennett D, Smith DJ.
    Am J Cardiovasc Drugs; 2010 Apr 01; 10(1):37-48. PubMed ID: 20104933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.